



ASX Release

## Quarterly Cash Flow Report and Trading Update

### Quarter ended 31 December 2017

**Melbourne, Australia; 31 January 2018:** Jayex Healthcare Limited (ASX: JHL) (**Jayex** or **Company**), a leading e-health provider of integrated healthcare services delivery platforms, today released its Appendix 4C – Quarterly cash flow report for the quarter ended 31 December 2017 (the **Quarter**).

During the Quarter JHL's consolidated cash receipts amounted to approximately AUD\$1.8m. Receipts derived from the UK represented approximately 85% of consolidated cash receipts.

Cash at bank over the quarter moved from \$1.124m to \$1.015m.

Operationally the Company continues to deploy its technologies of *Appointuit* (patient engagement) and the *Enlighten* Patient Flow Management Platform (patient arrival registration via kiosks, calling screens and wayfinding technologies) across the UK, Australia and New Zealand.

During the quarter the Company's UK operations were behind budget and are slightly behind budget for the year to date. The UK operation recorded invoiced revenue of approximately £775K for the quarter and £3.89M for the year to date (approximately A\$1.3m for the quarter and \$A6.5m year to date).

#### Contacts for further information:

Chief Executive Officer  
Nick Fernando  
1300 330 611  
[n.fernando@jayex.com](mailto:n.fernando@jayex.com)

Company Secretary  
Melanie Leydin  
0417 663 119

---

**About Jayex Healthcare Limited - [www.jayexhealthcare.com.au](http://www.jayexhealthcare.com.au)**

Jayex Healthcare is a leading provider in the United Kingdom and Australia of integrated healthcare services delivery platforms, incorporating the Company's four interconnected and proprietary technologies, being:

- the *Enlighten* patient workflow platform;
- the *Appointuit* patient engagement solution;
- the *Pharmacy Delivery 2 U* prescription delivery service; and
- the *BluePoint*® remote pharmacy prescription processing and dispensing terminal.

## Appendix 4C

### Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

**Name of entity**

JAYEX HEALTHCARE LIMITED

**ABN**

15 119 122 477

**Quarter ended ("current quarter")**

31 DECEMBER 2017

<b>Consolidated statement of cash flows</b>	<b>Current quarter</b>	<b>Year to date</b>
	<b>\$A'000</b>	<b>(12 months)</b>
		<b>\$A'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	1,801	8,789
1.2 Payments for		
(a) research and development	(64)	(221)
(b) product manufacturing and operating costs	(681)	(2,839)
(c) advertising and marketing	(75)	(320)
(d) leased assets	(96)	(373)
(e) staff costs	(953)	(4,169)
(f) administration and corporate costs	(845)	(3,291)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	-	-
1.5 Interest and other costs of finance paid	(85)	(139)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other (provide details if material)	-	-
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(998)</b>	<b>(2,563)</b>

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire:		
(a) property, plant and equipment	-	(18)
(b) businesses (see item 10)	-	-
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.2 Proceeds from disposal of:		
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	-	-
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.3 Cash flows from loans to other entities		
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material)	-	-
<b>2.6 Net cash from / (used in) investing activities</b>	<b>-</b>	<b>(18)</b>

<b>3. Cash flows from financing activities</b>		
3.1 Proceeds from issues of shares	-	-
3.2 Proceeds from issue of convertible notes	-	-
3.3 Proceeds from exercise of share options	-	-
3.4 Transaction costs related to issues of shares, convertible notes or options	-	-
3.5 Proceeds from borrowings	885	2,955
3.6 Repayment of borrowings	-	(670)
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other (provide details if material)	-	-
<b>3.10 Net cash from / (used in) financing activities</b>	<b>885</b>	<b>2,285</b>

<b>Consolidated statement of cash flows</b>		<b>Current quarter</b>	<b>Year to date</b>
		<b>\$A'000</b>	<b>(12 months)</b>
			<b>\$A'000</b>
<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of quarter/year to date	1,124	1,334
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(998)	(2,563)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	(18)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	885	2,285
4.5	Effect of movement in exchange rates on cash held	4	(23)
<b>4.6</b>	<b>Cash and cash equivalents at end of quarter</b>	<b>1,015</b>	<b>1,015</b>

<b>5.</b>	<b>Reconciliation of cash and cash equivalents</b>	<b>Current quarter</b>	<b>Previous quarter</b>
	at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>\$A'000</b>	<b>\$A'000</b>
5.1	Bank balances	1,015	1,124
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>1,015</b>	<b>1,124</b>

<b>6.</b>	<b>Payments to directors of the entity and their associates</b>	<b>Current quarter</b>
		<b>\$A'000</b>
6.1	Aggregate amount of payments to these parties included in item 1.2	(176)
6.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	-
6.3	Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2	

Directors fees, loan interest and premises lease payments for the quarter.

7. <b>Payments to related entities of the entity and their associates</b>	Current quarter \$A'000
7.1 Aggregate amount of payments to these parties included in item 1.2	-
7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3	-
7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	

Nil

8. <b>Financing facilities available</b> <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1 Loan facilities	2,885	2,885
8.2 Credit standby arrangements	-	-
8.3 Other (please specify)	-	-
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

Facility amount	Lender	Interest rate	Secured/unsecured
\$2,000,000	Covenant Holdings (WA) Pty Ltd	8.0% per annum	Unsecured
\$830,000	Covenant Holdings (WA) Pty Ltd	12.0% per annum	Unsecured
\$55,000	Covenant Holdings (WA) Pty Ltd	Interest free	Unsecured


9. <b>Estimated cash outflows for next quarter**</b>	\$A'000
9.1 Research and development	13
9.2 Product manufacturing and operating costs	279
9.3 Advertising and marketing	2
9.4 Leases	80
9.5 Staff costs	1,109
9.6 Administration and corporate costs	548
9.7 Other (provide details if material)	-
<b>9.8 Total estimated cash outflows</b>	<b>2,031</b>

*\*\* Please note that the above estimated cash outflows for the next quarter do not include inflows of receipts from customers. The cash outflows are estimates only and variable outflows are calculated on forecast revenue for the quarter. Variable outflows will change if actual revenue differs from forecast revenue.*

10. Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1 Name of entity		
10.2 Place of incorporation or registration		
10.3 Consideration for acquisition or disposal		
10.4 Total net assets		
10.5 Nature of business		

**Compliance statement**

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.



Sign here: .....  
 (Company secretary)

Date: 31 January 2018

Print name: Melanie Leydin

**Notes**

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.